Liver cancer is the third leading cause of cancer-related deaths worldwide， among which hepatocellular carcinoma （HCC） accounts for approximately 90% in primary liver cancer. The advances in diagnostic and treatment tools， along with a deeper understanding of their application， are transforming the treatment modality for patients. The application of these innovations in clinical practice faces challenges and requires guidance， and related clinical practice guidelines provide the latest recommendations for the management of HCC patients and conduct a comprehensive review of related data. In the 2024 EASL guidelines， a multidisciplinary team from multiple specialties conducts a multi-parameter assessment of individual risks and benefits from the perspective of patients.